

DIFICID (tocilizumab)

**GPI CODING:**

03530025000320

**DESCRIPTION:**

Fidaxomicin is a macrolide that is bactericidal against *C. difficile* in vitro, inhibiting RNA synthesis by RNA polymerases.

**APPROVAL DURATION:**

Approval duration: 10 days

**CRITERIA FOR DIFICID**

- I. Patient demonstrated an inadequate treatment response to Vancocin (vancomycin hydrochloride) after a trial of at least 14 days **OR**
- II. Patient experienced an intolerance to, an adverse event with, or has a documented contraindication to Vancocin (vancomycin hydrochloride) that would prohibit a trial of at least 14 days